Lyndra Therapeutics today announced that its LYNX™ drug delivery platform was named the winner of the Fierce Life Sciences Innovation Awards 2022 award in the Drug Delivery Technology category.
“We are thrilled at this recognition of the LYNX™ platform, which we are using to pioneer long-acting oral medicines,” said Dr. Patricia Hurter, CEO of Lyndra Therapeutics. “We have the chance to truly transform the experience of patients, delivering medicine in an optimal way and making it simpler and easier for them to be adherent. It is an honor to have the platform selected by the Fierce award judges in such a competitive category.”
The Fierce Life Sciences Innovation Awards, produced by Fierce Biotech and Fierce Pharma, showcase outstanding innovations that are transforming the life sciences industry. The awards are judged on the ability of the applicant to demonstrate effectiveness, technical ingenuity, competitive advantage, financial impact and true innovation.
The LYNX™ drug delivery platform harnesses more than 50 patented innovations in design, engineering and materials science to achieve dramatically reduced dosing frequency. The platform has the potential for broad applicability across multiple therapeutic areas – including approved drugs and those currently in development. Lyndra has formulated 24 therapies in the lab and achieved clinical proof of concept in 4 therapeutic areas.
The company’s lead asset is oral weekly risperidone (LYN-005) for people living with schizophrenia and bipolar 1 disorder. Pivotal trials are planned to initiate in the coming months.
Additional research is underway in cardiovascular and cardiometabolic diseases, opioid use disorder, malaria and oral contraception. Lyndra’s program investigating oral weekly levomethadone (LYN-014) for opioid use disorder has received Fast Track designation from the FDA.
“Winners of the Fierce Life Sciences Innovation Awards represent those that champion innovation in the face of great competition,” said Rebecca Willumson, SVP & Publisher of Fierce Biotech and Fierce Pharma. “We are very proud of this year’s class and send our congratulations to all of the Innovation Award winners.”
Lyndra’s LYNXTM Drug Delivery Platform
The LYNX™ drug delivery platform is one of the most significant advances in oral drug delivery in decades, creating medicines that last for a week or longer in an oral dosage form. A key aspect of the platform is its ability to deliver the drug consistently, minimizing peaks and troughs of drug levels compared to daily medicine. Based on technology invented in the Langer Lab, the LYNX™ platform has progressed rapidly since 2015 through preclinical and early human studies and achieved proof of concept of the platform and lead asset in a recently completed Phase 2 study. The LYNX™ drug delivery platform has the potential for broad applicability across multiple therapeutic areas – including approved drugs and those currently in development. The LYNX™ drug delivery platform offers the potential to increase adherence and improve health outcomes, while also freeing people from the burden of daily pills and simplifying their lives.
About Lyndra Therapeutics
Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders, which would benefit from dramatically reduced dosing frequency. Lyndra’s lead product candidate, oral weekly risperidone (LYN-005), is being developed for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform to tackle major public health and global health challenges, with therapies that include oral weekly levomethadone and oral weekly buprenorphine for opioid use disorder, a monthly oral contraception pill and oral biweekly ivermectin for malaria eradication. Since the founding of Lyndra, the company has received funding from the Bill & Melinda Gates Foundation, the NIH, AbbVie and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA and has a state-of-the-art GMP manufacturing facility in Lexington, MA. For more information, visit https://lyndra.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005864/en/
Contacts
Dan Boyle
Orangefiery
dan@orangefiery.com
(818) 209-1692
